Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and ...

US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant ...

Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual ...

BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...

Vivoryon Therapeutics announces Phase II trial results for varoglutamstat, showing no efficacy in cognitive endpoints but ...

MaaT Pharma reports Phase II results for MaaT013 in acute graft-versus-host disease, showing significant survival benefits ...

Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk ...

Johnson & Johnson’s Carvykti demonstrates strong Phase III CARTITUDE-4 results in multiple myeloma, achieving 89% MRD ...

Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM; USA, France, Germany, Italy.

US legislation aimed at safeguarding the country’s interests against potential security threats from China—is facing further ...

Sanofi’s Sarclisa shows significant Phase III results for multiple myeloma, delivering deeper and longer-lasting responses in ...